West Nile virus
| Amantadine | WNV | Viroporin inhibitor; blocks viral ion channel activity | Approved (other) | Japan | Viral ion channel (viroporin) | |
| Amodiaquine | WNV | Methyltransferase inhibitor | Preclinical | — | Human HNMT | |
| Aprotinin | WNV | Serine protease inhibitor | Preclinical | — | Human (multiple) | |
| Azaribine | WNV | Inhibition of Viral Genome Replication | Preclinical | — | Viral RNA pol | |
| Azauridine | WNV | Nucleoside analog | Preclinical | — | Viral RNA pol | |
| Brequinar | WNV | DHODH (DHODH) inhibitor | Preclinical | — | Human DHODH | |
| Chlorpromazine | WNV | Inhibits assembly of clathrin-coated pits at the plasma membrane | Preclinical | — | Human (multiple) | |
| Cyclosporine | WNV | Calcineurin inhibitor; allows for inhibition of T cell activation | Preclinical | — | Human CYPs | |
| Fenretinide | WNV | Unclear | Preclinical | — | Human RAR | |
| Galidesivir | WNV | RNA-dependent RNA polymerase (RdRp) inhibitor | Preclinical | — | Viral RNA pol | |
| Glycyrrhizin | WNV | 0 | Preclinical | — | Human TNF | |
| Labyrinthopeptin A1 | WNV | Interference with viral phospholipid membrane | Preclinical | — | Viral membrane | |
| Labyrinthopeptin A2 | WNV | viral membrane lipid phosphatidylethanolamine | Preclinical | — | Viral membrane | |
| Manidipine | WNV | Calcium channel blocker | Preclinical | — | Human ion channel | |
| Minocycline | WNV | Bacterial protein synthesis inhibitor by binding with the 30S ribosomal subunit. | Preclinical | — | Human (multiple) | |
| Obatoclax | WNV | Bcl-2 family inhibitor | Preclinical | — | Human MCL1 | |
| Ribavirin | WNV | Nucleoside inhibitor; Guanosine (ribonucleic) analog | Approved (other) | Japan | Viral RNA pol | |
| Tilorone | WNV | Interferon inducer | FDA approved | FDARussia | Unknown | |
| Tipranavir | WNV | Protease inhibitor | Preclinical | — | Viral protease | |
| Umifenovir | WNV | — | Preclinical | — | Human (multiple) | |
| Valproic Acid | WNV | HDAC inhibitor | Preclinical | — | Human HDAC |